Mr. Stephen Mulvany:

I cannot remember the name of the journalist. There has been media comment intimating that the HSE would lose substantial savings because it was not ready for a particular drug coming off patent and having a bio-similar available for it. That is not true. The HSE will be available from 1 November and those approvals will be in place subject to the bio-similar suppliers having stock and having made the necessary applications, some of which have already started.